Emerging drugs for the treatment of hereditary angioedema due to C1-inhibitor deficiency
- 3 April 2022
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Emerging Drugs
- Vol. 27 (2) , 103-110
Abstract
Hereditary angioedema due to C1-inhibitor (C1-INH-HAE) is a rare disease characterized by unpredictable swelling attacks that may be life-threatening when affecting the upper airways. Understanding...Keywords
This publication has 18 references indexed in Scilit:
- Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema AttacksJAMA, 2018
- Emerging Therapies in Hereditary AngioedemaImmunology and Allergy Clinics of North America, 2017
- Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 InhibitorNew England Journal of Medicine, 2017
- Current treatment options for hereditary angioedema due to C1 inhibitor deficiencyExpert Opinion on Pharmacotherapy, 2015
- Critical appraisal of androgen use in hereditary angioedema: a systematic reviewAnnals of Allergy, Asthma & Immunology, 2015
- Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working GroupAllergy, 2014
- Therapeutic management of hereditary angioedema due to C1 inhibitor deficiencyExpert Review of Clinical Immunology, 2013
- Metallopeptidase activities in hereditary angioedema: Effect of androgen prophylaxis on plasma aminopeptidase PJournal of Allergy and Clinical Immunology, 2008
- Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patientsAnnals of Allergy, Asthma & Immunology, 2008
- Hereditary AngioedemaArchives of internal medicine (1960), 2001